R Squared’s Cogent Biosciences COGT Stock Holding History

R Squared’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-910	Closed	-$7.1K	–	552
2024 Q4	$7.1K	Buy	+910	New	+$9.07K	0.01%	1240

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

R Squared's COGT Position: Q1 2025 in Review

R Squared sold out of Cogent Biosciences (COGT) in Q1 2025, closing a stake of 910 shares — an estimated $7.1K sold.

R Squared first reported a position in COGT in Q4 2024 and held it in 1 quarter. The position peaked at $7.1K in Q4 2024. 186 funds tracked by Wall St. Rank hold COGT as of Q1 2025.

R Squared reported no remaining Cogent Biosciences position as of Q1 2025 after selling out during the quarter.
R Squared sold 910 Cogent Biosciences shares in Q1 2025, an estimated $7.1K.
R Squared first reported a position in Cogent Biosciences in Q4 2024 and held it in 1 quarter.
R Squared's Cogent Biosciences position peaked at $7.1K in Q4 2024.
186 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.